|
Mar 19
|
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
|
|
Mar 18
|
Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High?
|
|
Mar 11
|
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
|
|
Mar 10
|
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
|
|
Mar 9
|
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
|
|
Mar 9
|
Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors
|
|
Mar 4
|
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
|
|
Mar 4
|
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
|
|
Feb 16
|
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 14
|
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
|
|
Jan 29
|
Are Medical Stocks Lagging AlloVir (ALVR) This Year?
|
|
Jan 29
|
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
|
|
Jan 14
|
Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program
|
|
Jan 14
|
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
|
|
Jan 12
|
Best Momentum Stocks to Buy for January 11th (Revised)
|
|
Jan 12
|
Are Medical Stocks Lagging Amarin (AMRN) This Year?
|
|
Dec 28
|
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
|
|
Dec 27
|
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
|
|
Dec 24
|
11 High Growth Micro-Cap Stocks to Buy
|
|
Dec 19
|
Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis
|